Anzeige
Mehr »
Dienstag, 09.06.2026 - Börsentäglich über 12.000 News
Pentagon in Alarmbereitschaft? Dieser Rohstoff könnte jetzt Gold in den Schatten stellen
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A41556 | ISIN: US87978U2078 | Ticker-Symbol: 3OS0
NASDAQ
09.06.26 | 19:24
1,250 US-Dollar
-1,57 % -0,020
Branche
Gesundheitswesen
Aktienmarkt
Sonstige
1-Jahres-Chart
TEMPEST THERAPEUTICS INC Chart 1 Jahr
5-Tage-Chart
TEMPEST THERAPEUTICS INC 5-Tage-Chart

Aktuelle News zur TEMPEST THERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
DoTempest Therapeutics erweitert Verwaltungsrat um zwei neue Mitglieder3
DoTempest Therapeutics appoints two directors to board1
DoTempest Therapeutics Appoints Drake Richey and John Yee, MD, MPH to Board of Directors78BRISANE, Calif., June 04, 2026 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST) ("Tempest" or "Tempest Therapeutics") today announced the appointment of two independent directors, Drake...
► Artikel lesen
29.05.Tempest Therapeutics, Inc. - 8-K, Current Report4
29.05.Tempest Therapeutics beschafft 2 Mio. US-Dollar durch Ausübung von Optionsscheinen5
29.05.Tempest Therapeutics Announces Warrant Exercise for Approximately $2 Million in Gross Proceeds2
22.05.Tempest Therapeutics, Inc. - 8-K, Current Report2
TEMPEST THERAPEUTICS Aktie jetzt für 0€ handeln
14.05.Tempest Therapeutics, Inc. - 10-Q, Quarterly Report1
14.05.Tempest Therapeutics: Tempest Reports First Quarter 2026 Financial Results and Provides Business Update287Announced positive interim data from the ongoing REDEEM-1 Phase 1/2a trial of TPST-2003 in patients with relapsed/refractory multiple myeloma (rrMM) Announced Cincinnati Children's Applied Gene and...
► Artikel lesen
06.05.Tempest Therapeutics: Tempest Presents Clinical Update at ISCT 2026 Annual Meeting3
06.05.Tempest Therapeutics, Inc. - 8-K, Current Report2
29.04.Tempest Therapeutics: Tempest to Advance Dual-Targeting CAR-T Platform with Clinical Update at ISCT 2026 Annual Meeting9
30.03.Tempest Therapeutics, Inc. - S-8, Securities to be offered to employees in employee benefit plans1
30.03.Tempest Therapeutics GAAP EPS of -$6.33 misses by $0.234
30.03.Tempest Therapeutics: Tempest Reports Year End 2025 Financial Results and Provides Business Update336Completed strategic acquisition of dual-targeting CAR-T assets from Factor Bioscience Inc. Named Matt Angel, Ph.D., Chief Executive Officer & President Announced positive interim data from the ongoing...
► Artikel lesen
30.03.Tempest Therapeutics, Inc. - 10-K, Annual Report3
30.03.Tempest Therapeutics, Inc. - 8-K, Current Report-
23.03.Tempest Therapeutics raises $2 million in private placement8
23.03.Tempest Therapeutics, Inc. - 8-K, Current Report1
11.03.Tempest Therapeutics: Tempest Announces Partnership for TPST-2003 in Preparation for Planned U.S. Registrational Study in 2026426Cincinnati Children's Applied Gene and Cell Therapy Center selected to conduct tech transfer, development and IND-enabling manufacturingAll activities other than long-term stability testing planned...
► Artikel lesen
Weiter >>
37 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1